ASP 0306

Drug Profile

ASP 0306

Alternative Names: ASP0306

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 12 May 2014 Discontinued - Phase-I for Benign prostatic hyperplasia in Japan (PO)
  • 01 Aug 2011 Phase I development in Benign prostatic hyperplasia is ongoing in Japan
  • 02 Aug 2010 Phase-I clinical trials in Benign prostatic hyperplasia in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top